Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

(2017) H. L. Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G).

(2017) I. McCaffery et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

(2009) P. J. Beltran et al.   MOLECULAR CANCER THERAPEUTICS

Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway

(2008) Eddy Himpe et al.   JOURNAL OF ENDOCRINOLOGY

IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

(2008) S. John Weroha et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer

(2008) P. D. Ryan et al.   ONCOLOGIST